Cannovum AG

  • WKN: A2LQU2
  • ISIN: DE000A2LQU21
  • Land: Deutschland

Nachricht vom 29.06.2021 | 08:28

Cannovum AG enters the full-spectrum cannabis extract market

DGAP-News: Cannovum AG / Key word(s): Product Launch
29.06.2021 / 08:28
The issuer is solely responsible for the content of this announcement.

Cannovum AG (stock exchanges Düsseldorf, Munich, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) has signed a supply agreement for full-spectrum cannabis extracts through its licensed subsidiary, Cannovum Health eG. The manufacturer is a non-European pharmaceutical company with many years of experience in the extraction process. The extracts are distributed to pharmacies under Cannovum's own brand.

Herbal medicines develop their complete effect through the interaction of all herbal substances, the commonly called entourage effect. This important mode of action is preserved in cannabis extracts obtained from the full spectrum of the plant.

Cannabis extracts are becoming increasingly important in the market across Europe. In Germany, steady growth is emerging over the last three years, with pharmacy purchases of extracts rising from 4.8 liters in 2017 to more than 1,300 liters in 2020, with the first half of last year alone seeing a 63% growth in purchase volume.

"We want to supply patients in Germany and Europe with medical cannabis. Full-spectrum extracts play an important role in this, because their mode of action and ease of oral application offer another therapeutic option. This allows us to cover the full therapeutic spectrum and reach a large patient group," says Pia Marten, CEO of Cannovum AG.

The inclusion of cannabis extracts in the product portfolio is an important step towards making cannabis-based therapies possible across the board. Cannovum supports physicians and pharmacists in caring for patients through a complete medical cannabis portfolio. This gives physicians the opportunity to fully customize the therapy for their patients, because every patient deserves the best therapy.


Linda Rasch, IR & PR, Cannovum AG
Phone +49 30 3982 163 62,

Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

For more information, visit

29.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“


Cryptology Asset Group PLC: 120 % Kurspotenzial

GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.

News im Fokus

RWE Aktiengesellschaft: RWE AG erhöht Konzern-Ergebnisprognose für das Geschäftsjahr 2021

30. Juli 2021, 08:52

Aktueller Webcast


H1 2021 Analyst Call

04. August 2021

Aktuelle Research-Studie

Vectron Systems AG

Original-Research: Vectron Systems AG (von GBC AG): Buy

30. Juli 2021